NDAORALCAPSULE, EXTENDED RELEASE
Approved
Apr 2021
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
3/8 — Basic
Drug data last refreshed 6h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
QELBREE (viloxazine hydrochloride) is an extended-release oral capsule approved in April 2021 for ADHD treatment. It is a selective norepinephrine reuptake inhibitor (NRI) that enhances norepinephrine availability in the central nervous system. The drug represents a non-stimulant alternative in the ADHD therapeutic landscape.
$4.0MPart D
Peak8.6 years to LOEProduct is in peak commercial phase with modest Medicare Part D penetration; team focus is on market share expansion and utilization optimization.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
QELBREE roles are concentrated in commercial execution and market penetration given peak-stage lifecycle and modest current claims volume. Career opportunities will emphasize driving formulary access, physician adoption, and competitive positioning in the non-stimulant ADHD segment. Long patent protection (8.7 years) ensures sustained brand team investment through the LOE horizon.
Brand Manager
Worked on QELBREE at Supernus Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.